Krystal Biotech announced the first patient has been dosed in EMERALD-1, its phase 1/2 clinical trial evaluating KB801 for ...

KALA Bio completes enrollment in CHASE trial, advancing KPI-012 for treating persistent corneal epithelial defects. Topline results are expected by the end of Q3 2025.

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on ...

Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PI ...

PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), ...

Pulsed eddy current (PEC) testing is a nondestructive testing (NDT) method, which is highly suitable for thickness measurement and sub-surface-defect detection. In this article, PEC testing is ...

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...

Amgen (AMGN) announced on Monday that a late-stage study evaluating its Bemarituzumab in combination with chemotherapy met ...

The quest for cutting-edge materials for sustainable energy technology, particularly for fabricating supercapacitors (SCs), has spiked in recent years due to the global intent to promote electric ...

“The Defects” writer Ahn So Jung has shared behind-the-scenes stories about the upcoming series! Based on a popular webtoon, “The Defects” is an action ...

Corneal ulcer occurs in 10% of the population of VKC patients. If left untreated, a plaque containing fibrin and mucus is deposited over the epithelial defect.